Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.64 |
| ▸ | RET | P07949 | 6/20 | 0.58 |
| ▸ | CDK2 | P24941 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.58 |
| ▸ | CDK1 | P06493 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | GSK3A | P49840 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | CDK7 | P50613 | 2/20 | 0.58 |
| ▸ | CDK9 | P50750 | 2/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768013 | 0.82 | KDR (0.59) | TLK2PDPK1RETCDK2KDR | |
| SCHEMBL1538367 | 0.82 | KDR (0.59) | TLK2PDPK1RETCDK2KDR | |
| SCHEMBL6389451 | 0.82 | KDR (0.58) | PDPK1RETCDK2KDRCDK1 | |
| SCHEMBL6389448 | 0.82 | KDR (0.58) | PDPK1RETCDK2KDRCDK1 | |
| SCHEMBL6390272 | 0.82 | RET (0.62) | PDPK1RETKDRFGFR1FLT3 | |
| SCHEMBL6390271 | 0.82 | RET (0.62) | PDPK1RETKDRFGFR1FLT3 | |
| SCHEMBL6389287 | 0.82 | LRRK2 (0.62) | RETRPS6KA3PDGFRBLRRK2SIRT1 | |
| SCHEMBL6389284 | 0.82 | LRRK2 (0.62) | RETRPS6KA3PDGFRBLRRK2SIRT1 | |
| SCHEMBL6393587 | 0.81 | TLK2 (0.65) | TLK2PDPK1KDRCDK1FGFR1 | |
| SCHEMBL6393582 | 0.81 | TLK2 (0.65) | TLK2PDPK1KDRCDK1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035251-A1 | BioMarkers for the Progression of Alzheimer's Disease | HE YUNSHENG | 2010-02-11 | — | — | US | disclosed |
| EP-2035582-A2 | BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE | Novartis AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007149798-A2 | BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE | NOVARTIS AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035251-A1 | BioMarkers for the Progression of Alzheimer's Disease | LRRK2, PSEN2, CLK2 | TLK2 9/4885PDPK1 165/4885RET 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.